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Background: Acromegaly is a rare disease primarily caused by growth hormone (GH)-secreting pituitary adenomas, and its treat-
ment is costly. Moreover, some patients are unresponsive to treatment. Hence, there are increasing efforts to develop new drugs with 
improved effectiveness for this disease. BIM23B065 is a novel chimeric molecule that acts on both somatostatin and dopamine re-
ceptors. This study aimed to investigate the effects of BIM23B065 compared with those of a somatostatin receptor analog and a do-
pamine agonist. 
Methods: The effects of BIM23B065 on the proliferation, GH and insulin-like growth factor-1 (IGF-1) levels, and extracellular sig-
nal-regulated kinase (ERK) 1/2 and cyclic AMP response element binding (CREB) phosphorylation of GH3 cells were investigated 
with MTS assay, enzyme-linked immunosorbent assay, and Western blotting, respectively. The dosage and treatment duration of 
BIM23B065 were tested in animal models of GH-secreting pituitary adenoma. The effect of BIM23B065 (3 mg/kg/day) on changes 
in IGF-1 levels before and after treatment was further investigated.
Results: In vitro, BIM23B065 treatment decreased GH release in the culture media and downregulated ERK 1/2 and CREB phos-
phorylation to 22% and 26%, respectively. In vivo, IGF-1 expression decreased to 50 % after 4 weeks of treatment with BIM23B065 
using an osmotic pump implant. Moreover, magnetic resonance imaging results showed that the tumor size decreased significantly 
following treatment with BIM23B065 for 4 weeks. 
Conclusion: The novel chimeric molecule was effective in decreasing IGF-1 and GH levels and may serve as an effective therapeutic 
agent for acromegaly.
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INTRODUCTION
Acromegaly is a disease characterized by chronic growth hor-
mone (GH) and insulin-like growth factor-1 (IGF-1) hyperse-
cretion [1,2]. It is primarily caused by a GH-secreting pituitary 
adenoma. Although surgical resection of the pituitary adenoma 
is the first choice of treatment for many patients, it restores nor-
mal IGF-1 levels in less than 60% of cases [1,2]. In patients un-
suitable or unwilling to undergo surgery, or in whom surgery 
fails to normalize plasma GH and IGF-1 concentrations, phar-
macological intervention is the standard procedure [1,2]. 
Somatostatin (SST) analogs and dopamine agonists (DAs) are 
useful in treating GH-secreting pituitary adenoma [3-5]. As GH-
secreting pituitary adenomas are associated with increased ex-
pression of SST and dopamine receptors, drugs targeting these 
receptors hold therapeutic potential against acromegaly [3-7]. 
However, they are relatively less effective for controlling hor-
monal secretion and reducing tumor sizes [2-8]. SST analogs, 
such as lanreotide, have been consistently shown to reduce hor-
monal hypersecretion in 60% to 70% of patients [1-3], whereas 
DAs, such as cabergoline (CAB), may be effective in up to 30% 
of patients with mildly elevated plasma IGF-1 concentrations 
[1,2]. SST and DAs are useful for the treatment of acromegaly, 
but they are not cost-effective and cases of unresponsiveness as 
well as resistance have been reported [9]. Therefore, there is a 
need for alternative pharmacological approaches to treat acro-
megaly.
Recently, a series of novel chimeric molecules consisting of a 
SST analog and a DA have been synthesized and are currently 
being tested [10-14]. The chimeric molecule used in this study 
acts on both SST receptors 2 and 5 as well as on dopamine re-
ceptor subtype 2; thus, it can be a promising candidate for the 
treatment of acromegaly and GH-secreting pituitary adenoma.
The main purpose of this study was to confirm the effect of 
BIM23B065 on GH-secreting pituitary adenoma and provide 
evidence for its approval as a new therapeutic option for acro-
megaly. Owing to increased efficiency via differentiated mecha-
nisms, this chimeric drug is expected to overcome the low rate 
of responsiveness to previously used drugs.
METHODS
Ethical statement
The Institutional Animal Care and Use Committee of Yonsei 
University Health System reviewed and approved (approval 
number: 2015-0403) all animal procedures. Experiments were 
carried out under the strict guidance of the Association for As-
sessment and Accreditation of Laboratory Animal Care. Ani-
mals were housed under standard conditions consisting of 12-
hour light/dark cycles (lights were turned on at 7:00 AM) and a 
temperature of 22°C to 24°C. The animals had ad libitum access 
to standard rodent chow and water, except during intended fast-
ing periods designated for specific experimental protocols. All 
mice were maintained in accordance with the American Associ-
ation of Laboratory Animal Care guidelines.
Cell culture
For in vitro experiments, the rat pituitary tumor cell line GH3 
(American Type Culture Collection) was used. These cells were 
grown in Dulbecco’s modified Eagle medium (DMEM)/high-
glucose medium supplemented with 10% fetal bovine serum 
and penicillin-streptomycin solution (Hyclone Co., Logan, UT, 
USA). The cells were placed in a culture incubator that main-
tained atmospheric conditions of 37°C and 5% CO2. The medi-
um was changed within 3 days, and the cells were split with 
trypsin/ethylenediaminetetraacetic acid (EDTA) every week.
Experimental animals
The animal model used in this study was a previously devel-
oped mouse model, which expressed the phenotype of GH-se-
creting pituitary adenomas [8]. A somatotroph-specific aryl hy-
drocarbon receptor interacting protein knockout (sAIPKO) 
mouse model was established using rGHp-Cretg/+; Aiplox/lox 
mice [15]. All mice in this study were males above 40 weeks of 
age because most sAIPKO mice develop GH-secreting pituitary 
adenomas as they age (>40 weeks). 
Cell proliferation assay 
To test the cytotoxicity of drugs, MTS assays were performed. 
GH3 cells (100 μL) were seeded in a 96-well plate at a density of 
4×103 cells/well. After 24 hours of incubation at 37°C in a 5% 
CO2 incubator, the growth medium was replaced with DMEM/
high-glucose medium without serum to induce starvation condi-
tions. After 12 hours, media containing three different drugs, 
namely lanreotide (5, 10, 50, 100, or 250 μM), CAB (3, 5, 7, 10, 
or 15 μM), and BIM23B065 (5, 10, 50, 100, or 250 μM) were 
prepared. The control group was treated with dimethyl sulfoxide 
(DMSO). After treatment with drugs, the cells were incubated 
for 24, 48, and 72 hours in the incubator. 
MTS solution (Promega, Madison, WI, USA) was diluted by 
mixing 150 μL of the solution with 1 mL of medium. The cells 
were treated with MTS medium for 1.5 hours in the incubator. 
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The optical density was observed under 495 nm using a spectro-
photometer (Versa Max microplate reader, Molecular Devices, 
San Jose, CA, USA).
GH and IGF-1 ELISA
The medium collected from the cell culture was tested for 
changes in GH levels before and after drug treatment. To deter-
mine the effect of the drug in normalizing GH and IGF-1 levels 
in the animal model, blood serum samples collected before and 
after treatment were tested. GH and IGF-1 levels were mea-
sured using rat/mouse growth hormone enzyme-linked immu-
nosorbent assay (ELISA) kit 96-Well Plates (Millipore, Billeri-
ca, MA, USA) and mouse IGF-1 ELISA kit (Abcam, Cam-
bridge, UK), respectively, according to the manufacturer’s in-
structions. 
Western blotting
Before drug treatment, the cells were seeded and stabilized for 
24 hours. After treatment with drugs for 15 minutes, the plates 
were washed twice with 1X Dulbecco’s Phosphate-Buffered 
Saline. The plates were then kept on ice and treated with protein 
lysis buffer, which is composed of 10% glycerol, 50 mM Na-
3VO4, 100 mM NaF, 100 mM phenylmethylsulfonyl fluoride, 
and 100 mM dithiothreitol mixed in radioimmunoprecipitation 
assay (RIPA) buffer. The cells were collected in 1.5 mL micro-
centrifuge tubes using a cell scraper and incubated on ice for 1 
hour with frequent mixing. The samples were then centrifuged 
for 20 minutes at 15,380 g, and the supernatant was transferred 
to new Eppendorf tubes. 
The protein concentrations were measured using Bradford as-
say (Bio-Rad laboratories, Hercules, CA, USA) and set to 50 
μM for all samples. The samples were prepared with 10% sodi-
um dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) buffer and denatured in a heating block at 95°C for 5 
minutes. 
Proteins were separated by size using gel electrophoresis and 
transferred to Immobilon polyvinylidene difluoride membranes 
by wet transfer technique. The obtained membranes were 
blocked with 5% skim milk for 1 hour to prevent non-specific 
binding with antibodies and probed with anti-phospho-cyclic 
AMP response element binding (CREB) (1:1,000, Cell Signal-
ing Technology, Danvers, MA, USA), anti-total-CREB 
(1:1,000, Cell Signaling Technology), anti-phospho-extracellu-
lar signal-regulated kinase (ERK) 1/2 (1:2,000, Cell Signaling 
Technology), anti-total ERK 1/2 (1:4,000, Cell Signaling Tech-
nology) overnight at 4°C. The membrane was washed in 1X 
TBS-T solution and reacted with the secondary antibody 
(1:4,000, Thermo Fisher Scientific, Waltham, MA, USA) for 
another 1 hour at room temperature. After TBS-T washing, pro-
teins on the membrane were detected using a West Save Up 
Western Blot detection kit (AbFrontier #LF-QC0101) on an en-
hanced chemiluminescence film.
Osmotic pump implantation
Establishment of the knockout model was confirmed by geno-
typing. To determine the dosage of the new chimeric molecule 
drug, three different doses of the drug were tested on sAIPKO 
mice. In total, 16 male mice (>40 weeks of age) were divided 
into four groups (vehicle, lanreotide, CAB, and chimeric mole-
cule groups) of four mice each.
The drug was administered for 7 days using Alzet mini-os-
motic pumps (Durect Co., Cupertino, CA, USA). Osmotic pump 
was prepared according to the manufacturer’s protocol. The 
drug concentration was calculated individually based on animal 
weight. For implantation surgery, the animals were subjected to 
anesthesia using isoflurane. After blood was withdrawn by retro-
orbital bleeding, the pump was implanted under the epidermis 
on the dorsal posterior side of the animals as the incision wound 
was clipped. Blood glucose level and body weight were mea-
sured daily to monitor the condition of the animals.
After the concentration was set, the four groups were treated 
for one month. To reduce the stress associated with the insertion 
of the drug-release pumps, a 14-day release pump was used in-
stead of a 7-day release pump. The test concentration of lanreo-
tide was set at the same molar concentration as BIM23B065. 
CAB concentration was set based on previous animal studies 
[16,17]. The procedure and protocols were the same as the pre-
vious experiment, save for the pump type and monitoring fre-
quency. The pump type was changed to 14-day release pump so 
that the pump was changed to a newly prepped pump after 2 
weeks. In addition, the condition of animals was monitored ev-
ery other day. 
Lanreotide and BIM23B065 were provided by Ipsen (Boston, 
MA, USA) and CAB was purchased from Dongkoo Bio & 
Pharma (Seoul, Korea).
Magnetic resonance imaging 
All magnetic resonance imaging (MRI) experiments were per-
formed on a 9.4T Bruker BioSpec 94/20 USR small animal im-
aging system (Bruker BioSpin MRI GmbH, Ettlingen, Germa-
ny) equipped with 1H mouse body coil. T2-weighted MRI scan 
was performed, and tumor size was measured using OsiriX DI-
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COM viewer before and after treatment with the chimeric mol-
ecule. The tumor volume was estimated according to equation 1: 
tumor volume=(length×width2)/2 [18].
Statistical analyses 
Statistical analysis was performed using Microsoft Excel (Mi-
crosoft, Redmond, WA, USA). The results are expressed as 
mean±standard error of the mean of the results from three inde-
pendent experiments with similar patterns. Differences were as-




The half maximal inhibitory concentration (IC50) in GH3 cells 
was measured to determine the effect of the chimeric molecule 
as well as that of the positive controls (CAB and lanreotide). 
After 72 hours of treatment with 250 µM BIM23B065, the cell 
viability decreased to 43%. Cell viability decreased to 53% and 
49% after 72 hours of treatment with 250 µM lanreotide and 15 
µM CAB, respectively (Fig. 1A). 
Changes in CREB and ERK 1/2 phosphorylation 
After the proliferation assay, each drug was tested at the IC80 
concentration to evaluate their effects on GH3 cells by checking 
CREB and ERK 1/2 phosphorylation. After 15 minutes of treat-
ment, BIM23B065 decreased CREB phosphorylation by ap-
proximately 26%, while lanreotide and the combination of CAB 
and lanreotide decreased CREB phosphorylation by only 16% 
and 18%, respectively. CAB decreased CREB phosphorylation 
by 9%. BIM23B065 and lanreotide downregulated p-ERK 1/2 
level by 22% compared to the control. However, CAB and the 
combination of lanreotide and CAB did not decrease p-ERK 
level (Fig. 1C).
GH level in the cell medium
Based on the results of the cell proliferation assay, the cell me-
dium at 48 hours was used to determine the change in GH lev-
els. Compared with the control, all drugs decreased GH level in 
the medium. The GH level decreased by 3% with lanreotide 
treatment, while CAB showed the greatest decrement of ap-
proximately 13%. The combination of CAB and lanreotide ex-
hibited a decrement of approximately 12%, which is similar to 
the result of CAB, and BIM23B065 decreased the level of GH 
in the medium by approximately 10% (Fig. 1B).
Dose-dependent reduction of IGF-1 by BIM23B065 in 
sAIPKO mice 
sAIPKO mice aged 40 weeks or above were used because pitu-
itary adenoma incidences are reported at this age [8]. Consider-
ing that sex hormones affect the onset and aggressiveness of pi-
tuitary adenoma [8], female mice were excluded from the ex-
periment, and the effect of estrogen was avoided. 
Being a novel molecule, a dose-ranging study of BIM23B065 
was conducted in this animal model at doses of 3, 4, 5, and 6 mg/
kg/day. After 7 days of drug treatment, most animals showed 
dose-dependent decreases in IGF-1 levels. IGF-1 level decreased 
by 37% at the dose of 3 mg/kg/day and by 47% at doses of 4, 5, 
and 6 mg/kg/day (Fig. 2A). 
Body weight (Fig. 2B) and blood glucose level (Fig. 2C) re-
mained constant during the treatment, with no significant chang-
es observed before or after the treatment (Fig. 2B, C). 
Long-term effects of BIM23B065, lanreotide, and 
cabergoline
Based on the dosage decision experiment, 3 mg/kg/day was found 
to be an effective concentration and used for the BIM23B065 
treatment group. The mice were treated for 4 weeks with vehicle, 
BIM23B065, lanreotide, or CAB. Lanreotide was used at the 
same molar concentration as BIM23B065; therefore, its dosage 
was set to 2.257 mg/kg/day. CAB concentration was set to 0.82 
mg/kg/day based on previous reports.
After the treatment duration, IGF-1 levels decreased by 10% in 
the vehicle control group compared to the pre-treatment level, and 
by 18%, 50%, and 49% in the CAB lanreotide, and BIM23B065 
groups, respectively (Fig. 3A). No changes in body weight and 
blood glucose levels were observed throughout the experiment 
(Fig. 3B, C).
MRI analysis of tumor size before and after drug 
treatment
To determine the effect of BIM23B065 on tumor size, MRI was 
performed before and after 4-week treatment in five sAIPKO 
mice. Three of the five animals contained pituitary tumors and 
all five animals showed hyperplasia. Comparison of MRI results 
before and after treatment showed that the tumor size decreased 
by 50% after BIM23B065 treatment (Fig. 4A). The size of the 
pituitary hyperplasia also decreased in all five animals; howev-
er, it decreased by 59% in two mice with tumors (Fig. 4B). Pre- 
and post-treatment MRI results are presented in Fig. 4C.
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Fig. 1. Effects of lanreotide, cabergoline, and BIM23B065 on growth hormone 3 (GH3) cells. (A) Cell proliferation assay. (B) Change in 
growth hormone release in the medium after 48 hours of treatment. (C) Changes in phospho-cyclic AMP response element binding (p-
CREB) and phospho-extracellular signal-regulated kinase (p-ERK) 1/2 after 15 minutes of drug treatment. DMSO, dimethyl sulfoxide; 
LAN, lanreotide; CAB, cabergoline. aP<0.05. 
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Recently, the Acromegaly Guidelines reported that pharmaceu-
tical treatment as well as surgical interventions can be adminis-
tered as primary treatment options for acromegaly [1]. The 
drugs used for GH-secreting pituitary adenoma treatment act on 
both SST and dopamine receptors [1,2]. Although SST analogs 
and DAs have been reported for the treatment of GH-secreting 
pituitary adenomas, the response rate of SST is only between 
60% to 70%. Moreover, DAs are reported to be effective only in 
cases of mild hormonal activity [1]. Resistance to SST analogs 
has reduced the available treatment options. Therefore, a novel 
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chimeric drug (BIM-23A760) was first synthesized to circum-
vent the issue of unresponsiveness to existing drugs [10-14,19]. 
This new chimeric molecule, which is a combination of the two 
most commonly used drugs for the treatment of pituitary diseas-
es, is a potential drug candidate. 
SST analogs and DAs act via different mechanisms. SST ana-
logs have tumor static effects, while CAB (DA) causes apopto-
sis. As chimeric molecules exhibit two mechanisms, they are 
generally considered to possess the merits of both incorporated 
drugs and presumably have a synergistic effect. Previously syn-
thesized chimeric molecules (BIM-23A760) have exhibited in-
hibitory effects on pituitary hormones such as GH and prolactin 
(PRL); however, some molecules showed ineffective outcomes 
[11]. The examined chimeric molecule (BIM-23A760) present-
ed positive outcomes only in reducing tumor size in non-func-
tioning pituitary adenoma in vivo [13]. Moreover, it has also 
been reported to show inhibitory effects on the secretion of GH 
and PRL in vitro only [10,19]. The present study showed that 
the chimeric molecule BIM23B065 is also effective in a pitu-
itary adenoma mouse model. 
According to the study that investigated the effects of an earli-
er version of this chimeric molecule, it was shown to suppress 
GH and PRL secretion from human acromegaly tumor cell cul-
























































Fig. 2. Seven-day treatment of BIM23B065 at different concentrations. (A) Insulin-like growth factor-1 (IGF-1) level change in each group 
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well as their combination. This indicated that it acts on receptors 
other than SST receptors [19]. However, after multiple dosing, 
an active metabolite of BIM-23A760 was formed and interfered 
with the parent compound, after which BIM-23A760 develop-
ment was halted. Whereas, the main metabolite of BIM23B133 
did not interfere with the parent compound, BIM23B065 and did 
not bind to any of the SST receptors, so BIM23B065 is more ef-
fective in reducing GH level and tumor size than BIM-23A760 
[20].
The chimeric molecule (BIM23B065) in this study was com-
prised of a SST analog (lanreotide) and a DA (CAB) in a 1:1 ra-
tio. The chimeric molecule and not individual drugs was used 
because of heterodimerization between SST/DA receptor, as-
suming that the chimeric molecule interacts more effectively 
than individual drugs [11,19]. Being a novel agent and not just a 
mixture of two drugs, BIM23B065 was observed to be signifi-
cantly more effective in vitro than the mixture of lanreotide and 
CAB. In this study, we aimed to elucidate the mechanism of ac-
tion of BIM23B065 in GH3 cells by investigating cell prolifera-
tion at different concentrations, CREB and ERK 1/2 phosphory-
lation, and changes in GH release. 















































Fig. 3. Effects of lanreotide, cabergoline, and BIM23B065 after 4-week treatment in somatotroph-specific aryl hydrocarbon receptor inter-
acting protein knockout (sAIPKO) mice. (A) Change in insulin-like growth factor-1 (IGF-1) level after 4-week treatment with lanreotide 
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However, CAB was effective at a much lower concentration 
than those of the other two drugs. Assuming that the chimeric 
molecule is made of a direct combination of a SST analog and a 
DA, the concentration of lanreotide administered to the animals 
was set equivalent to that of the chimeric molecule. 
In vitro and in vivo tests confirmed that the chimeric molecule 
was effective in lowering pituitary hormone activity. The animal 
model used in the study was a novel acromegaly mouse model 
that exhibited the phenotype of pituitary hyperplasia and even-

































Fig. 4. Effects of BIM23B065 on tumor size and pituitary gland size in somatotroph-specific aryl hydrocarbon receptor interacting protein 
knockout (sAIPKO) mice. (A) Changes in average tumor volume after 4-week treatment. (B) Changes in average pituitary gland size after 
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demonstrated similar clinical features to human acromegaly, 
wherein increased secretion of GH and expression of SST re-
ceptor type 2 (SSTR2), SSTR5, and dopamine receptor type 2 
(DRD2) in the pituitary gland were observed. 
After 7 days of treatment with BIM23B065 in sAIPKO acro-
megalic mice, the level of IGF-1 was not uniformly decreased 
in each dosage group. It was assumed that the IGF-1 level was 
influenced by mechanical stress induced in the mice during the 
pump implant surgery. Additionally, the duration of the pump (7 
days) may have been too short for the drug to demonstrate its 
full effect. However, no change in body weight was observed, 
indicating that the drug was not toxic. Based on the results of 
this experiment, we performed a second 4-week study with the 
duration of the pump changed to 14 days, so that surgical inter-
vention was required only once during the entire treatment. 
BIM23B065 was delivered via the 14-day pump at a dose of 3 
mg/kg/day.
The results of the second animal experiment were relatively 
uniform. Body weights and blood glucose levels were stable 
throughout the entire experimental duration. The IGF-1 level 
significantly decreased after BIM23B065 treatment as com-
pared to after CAB and lanreotide treatment; the IGF-1 level in 
most of the BIM23B065-treated mice was reduced by 50% 
post-treatment.
Four weeks of treatment with BIM23B065 also significantly 
decreased tumor mass and size of the pituitary gland. Two of 
three sAIPKO mice with pituitary adenoma had hyperplastic tu-
mors. Although MRI results may not be significant, it showed 
the size of tumor and hyperplasia pituitary shrinkage. Therefore, 
BIM23B065 could possibly be used in patients with pre-tumor 
abnormalities. 
There are certain limitations to this study. First, the results 
showed that BIM23B065 had a similar effect to SST analogs, 
which was used as a positive control in the animal study. SST 
analog was ineffective in GH3 cells, but effective in animal 
model; however, the DA showed opposite effects. BIM23B065 
was effective both in GH3 cells and in the animal model. In-
deed, when applied to patients with sporadic GH-secreting pitu-
itary adenoma caused by various genome changes, chimeric 
molecules may be effective in patients with non-responsive to 
lanreotide, but human studies have not confirmed in this study. 
Second, the sample size (n=5) was small. All five animals had 
hyperplasia and three of them had tumors. The effects of the 
drug were observed in all the animals compared with the control 
group. Thus, the chimeric molecule is effective in both hyper-
plasia and pituitary tumors. Third, it was impossible to fully un-
derstand the effects of BIM23B065 on metabolic parameters. 
The physical activity and blood glucose levels of the animals 
remained stable throughout the study, but there may be compli-
cations associated with the use of the novel drug. No adverse ef-
fects were observed in the liver and kidney; however, other side 
effects could exist. Therefore, examination of long-term effects 
with a larger number of experimental animals will be required 
in further studies. Finally, dose-dependent experiments of lan-
reotide and CAB could not be carried out in GH-secreting pitu-
itary adenomas animal model. In the case of BIM series in both 
in vitro and in vivo, the treatment concentrations were deter-
mined after confirming the dose-dependent efficacy, and the 
same concentrations of lanreotide corresponding to the BIM se-
ries were treated. In the case of CAB, we proceeded with refer-
ence to existing paper references. Since we focus on the effects 
of the BIM series, the does-dependent experiments of lanreotide 
and CAB could not be carried out. Also, even in MRI results, 
the purpose of the study was to analyze the effects of biochemi-
cal activity on the primary end point. The analysis of tumor size 
changes in the animal model for the use of lanreotide and CAB 
did not proceed due to the limitation of the number of MRIs in 
experimental animals at the medical institution.
Previous studies have confirmed the inhibitory effect on cell 
proliferation and hormone secretion only in vitro [10-14,19]. 
This study showed that BIM23B065 effectively decreased not 
only GH release in GH3 cells, but also IGF-1 levels in a GH-se-
creting pituitary adenoma mouse model. The reduction of hor-
mone activity by BIM23B065 in vivo shows promising results 
for its future clinical use. However, GH levels remained un-
changed (data not shown). This could be because GH is released 
in a pulsatile manner every three hours and could not be moni-
tored at the accurate time. In addition, GH is a stress hormone 
that is sensitive to anesthesia or orbital venous congestion. The 
secretion of IGF-1, stimulated by GH, decreased. The chimeric 
molecule showed distinct effects compared to those of the com-
bination of lanreotide and CAB, indicating that this is a novel 
drug and not just a mixture of two drugs. Based on the results of 
this study, BIM23B065 holds potential to be developed into a 
novel therapeutic agent for acromegaly. Future studies are war-
ranted to investigate its effects further.
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